Effects of catecholamine-β-adrenoceptor-cAMP system on severe patients with heart failure

Objective To investigate the association between catecholamine-β-adrenoceptor (β-AR)-adenosine 3", 5"-monophosphate (cAMP) system and long-term prognosis in patients with chronic heart failure (CHF).Methods The study population comprised 73 patients with CHF (EF: 23% ± 10% ) with a mean follow-up of 3. 8 ± 1.9 years. Plasma levels of norepinephrine ( NE ) were measured using high performance lipid chromatography, β-adrenergic receptor density (Bmax) and the content of cAMP in peripheral lymphocytes were calculated using ^3H-dihydroalpneolo as ligand and competitive immunoassay, respectively. Deaths due to cardiovascular events within the follow-up period were registered.Results The total mortality was 64. 7%, 57. 4% of which was for cardiogenic (worsening heart failure: 32.4%; sudden death: 25. 0%). In the cardiogenic death group, plasma levels of NE and epinephrine (E) (3. 74 nmol/L ±0. 09 nmol/L and 3. 17 nmol/L ± 1.0nmol/L) and the contents of peripheral lymphocyte cAMP (3. 64 pmol/mg protein ± 1.4 pmol/mg protein ) were significantly increased as compared with the survival group (2.68 nmol/L ± 0. 07 nmol/L, 2. 41 nmol/L ± 0.24nmol/L and 2.73 pmol/mg protein ±0. 9 pmol/mg protein, respectively, all P

    推荐阅读